Oncopeptides Logo

Oncopeptides

Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.

ONCO | ST

Overview

Corporate Details

ISIN(s):
SE0009414576 (+4 more)
LEI:
549300J9WWQ5CBYQ1M77
Country:
Sweden
Address:
Luntmakargatan 46, 111 37 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oncopeptides AB is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers, particularly hematological diseases. Founded in 2000, the company leverages its proprietary Peptide Drug Conjugate technology platforms to develop innovative treatments. Its lead product, Pepaxti® (melflufen), is a treatment for adult patients with relapsed refractory multiple myeloma (RRMM). Oncopeptides is actively commercializing Pepaxti in Europe and conducts real-world evidence studies to support the drug's effectiveness and tolerability in clinical practice. The company's mission is to address significant unmet medical needs and provide hope to cancer patients through scientific innovation.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-08 09:50
ISS
English 10.5 KB
2025-09-30 10:00
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i Oncopeptides
Swedish 68.1 KB
2025-09-30 10:00
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in Oncopeptides
English 67.7 KB
2025-09-17 08:30
Share Issue/Capital Change
Oncopeptides’ rights issue oversubscribed to approximately 157 percent
English 86.0 KB
2025-09-17 08:30
Share Issue/Capital Change
Oncopeptides företrädesemission övertecknad till cirka 157 procent
Swedish 86.2 KB
2025-08-29 09:45
Major Shareholding Notification
Swedish 10.5 KB
2025-08-28 10:41
Major Shareholding Notification
Swedish 10.5 KB
2025-08-28 08:15
Share Issue/Capital Change
Oncopeptides publishes disclosure document regarding rights issue
English 91.2 KB
2025-08-28 08:15
Share Issue/Capital Change
Oncopeptides offentliggör informationsdokument avseende företrädesemission
Swedish 92.7 KB
2025-08-25 20:40
Share Issue/Capital Change
Oncopeptides enters into additional guarantee commitments, rights issue fully g…
English 83.4 KB
2025-08-25 20:40
Share Issue/Capital Change
Oncopeptides ingår ytterligare garantiåtaganden, företrädesemissionen fullt gar…
Swedish 85.1 KB
2025-08-25 10:10
Major Shareholding Notification
Swedish 10.6 KB
2025-08-21 08:00
Interim Report
Swedish 580.9 KB
2025-08-21 08:00
Interim Report
English 597.7 KB
2025-08-21 07:59
Share Issue/Capital Change
Oncopeptides carries out rights issue of approximately SEK 150 million and prov…
English 110.4 KB

Automate Your Workflow. Get a real-time feed of all Oncopeptides filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oncopeptides via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2021-11-24 Andrea Passalacqua Other Sell 5,000 68,550.00 SEK
2021-11-24 Fredrik Lehmann Other Buy 5,000 57,550.00 SEK
2021-09-14 Fredrik Lehmann Other Buy 1,000 42,760.00 SEK
2021-08-23 Anders Martin-Löf Other Buy 2,000 82,354.00 SEK
2021-08-20 Andrea Passalacqua Other Buy 5,000 193,400.00 SEK
2021-06-02 Nicolaas Bakker Other Buy 3,000 283,140.00 SEK
2021-05-28 Fredrik Lehmann Other Buy 2,000 200,000.00 SEK
2021-05-26 Nicolaas Bakker Other Buy 3,500 361,270.00 SEK
2021-05-26 Anders Martin-Löf Other Buy 2,000 204,184.00 SEK
2021-05-26 Stig Anders Jacob Lindberg Other Other 157,500 15,970,500.00 SEK

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.